CO SB168

Requires the Colorado medical assistance program pharmacy benefit to include extended-release opioid antagonist medications for medication-assisted treatment of substance use disorders

Permits pharmacists with collaborative practice agreements with prescribers to administer injectable medication-assisted treatment and receive enhanced dispensing fees equivalent to clinical provider administration fees

Defines "medication-assisted treatment" as a combination of behavioral therapy and FDA-approved medications to treat substance use disorders, including opioid antagonists

Declares that methadone, buprenorphine, and naltrexone must be equally available and accessible under the medical assistance program

Takes effect August 8, 2018, unless a referendum petition is filed, in which case it requires voter approval at the November 2018 general election